PAR1 (Thrombin Receptor / F2R) Drug Discovery Landscape & Assay Solutions
- By admin
- 24 Sep 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Fibrosis, and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PAR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAR1/F2R Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Ideal for binding assays and structural analysis. |
View PAR1 Products |
| Gene Delivery | PAR1 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Crucial for GPCR conformation preservation in functional assays. |
View PAR1 Products |
| Benchmark Ab | Anti-PAR1 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View PAR1 Products |
| Validator | PAR1 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View PAR1 Products |
| Related Target A | PAR2 Subfamily homolog. Essential for counter-screening to ensure off-target safety and selectivity. |
View PAR2 Products |
| Related Target B | Thrombin (F2) Upstream activating protease. Crucial for setting up enzymatic and cleavage-activation assays. |
View F2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Loss | Lentivirus-mediated stable cell line construction ensures native 7-transmembrane folding. |
| Subfamily Cross-Reactivity | PAR2 and PAR4 homolog panels available for precise counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA pool included for target knock-down confirmation. |
Live PAR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Protease-Activated Receptor 1 (PAR1, encoded by the F2R gene) is expanding beyond its classical role in antiplatelet therapy. While the FDA-approved small-molecule antagonist Vorapaxar established PAR1 as a major target for secondary prevention of myocardial infarction, the next wave of drug discovery is pivoting toward oncology (tumor microenvironment, cell migration, and metastasis) and inflammatory/fibrotic diseases.
Because PAR1 is a G-protein coupled receptor (GPCR) activated by thrombin cleavage, developing highly selective inhibitors requires tools that can capture both its inactive state and its unique tethered-ligand activated state. The current pipeline features a shift toward biased signaling modulators, pepducins, and highly specific monoclonal antibodies designed to block the thrombin-binding site without inducing off-target bleeding risks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules / Antagonists | Merck, Eisai | Thrombosis, Stroke Prevention | Calcium Flux & IP-One Assays (Need PAR1 Lentivirus for stable cell lines) |
| Monoclonal Antibodies | Academic Institutions, Biotech | Oncology, Fibrosis, Sepsis | Epitope Mapping & Binding Kinetics (Need high-purity extracellular domain proteins) |
| Pepducins / Peptides | Tufts Medical Center, Biotechs | Inflammation, Breast Cancer | Functional Signaling Assays (Need stable GPCR expression vectors) |